Journal of the National Cancer Institute Advance Access originally published online on October 9, 2007
JNCI Journal of the National Cancer Institute 2007 99(20):1497; doi:10.1093/jnci/djm213
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© Oxford University Press 2007.
|
|
MEMO TO THE MEDIA |
Prostate Cancer Therapy Linked to Increased Risk of Heart Disease Death
jncimedia@oxfordjournals.org
301-841-1287
| The first 10% of the full text of this article appears below. |
The use of androgen deprivation therapy to treat localized prostate cancer is associated with an increased risk of death from heart disease, according to a study published online October 9 in the Journal of the National Cancer Institute.
Androgen deprivation therapy is frequently used to treat high-risk localized prostate cancer. Studies have shown that androgen deprivation therapy, when used with external
Contact:
Citation:
Note to Reporters:
Related Articles in JNCI
![]()
CiteULike
Connotea
Del.icio.us What's this?
J Natl Cancer Inst 2007 99: 1516-1524.
J Natl Cancer Inst 2007 99: 1498-1499.
J Natl Cancer Inst 2007 99: 1821.